Combating Cancer with New Immunotherapy Treatments
Over the past decade, immunotherapies have revolutionized the way we treat cancer. This next generation of new cancer treatments is able to harness the body’s own defense mechanisms to attack cancer cells and halt tumor growth.
Cancer is more likely to affect older Canadians and awareness of the latest treatments is crucial so that you can be the best advocate for yourself or a loved one.
On the occasion of Cancer Immunotherapy Month this June, join Bill VanGorder (C.A.R.P.), Dr. Paul Wheatley-Price (Medical Oncologist at The Ottawa Hospital), Kathy Barnard (CEO of Save Your Skin Foundation), and Stephanie Michaud (President and CEO of BioCanRx) for a closer look at these pioneering new treatments and the promise they hold in helping older Canadians in the fight against cancer.
• Date: Monday, June 21, 2021
• Time: 1:00pm EDT
Please click here to register so that we know how many virtual spaces we need to accommodate .
CLICK HERE TO WATCH LIVE VIA ZOOM
This event is made possible with support from Merck Canada Inc
BIOGRAPHIES
Bill VanGorder, Chief Policy Officer at C.A.R.P.
• Bill has been the Chief Policy Officer at CARP since August 2020. He leads a staff team and hundreds of volunteers who advocate on behalf of older adults for better healthcare, financial security, and freedom from ageism
• He is also President of MRC Associates, Inc. a firm that works with Charities and not-for-profits to improve Board/Staff relations, management and systems
• He was the CEO of the Lung Association of Nova Scotia for 15 years
Dr. Paul Wheatley-Price
• Dr. Paul Wheatley-Price is Associate Professor in the Department of Medicine at the University of Ottawa, and a medical oncologist at The Ottawa Hospital Cancer Centre, specializing in the treatment of thoracic malignancies and carcinoma of unknown primary
• He is the medical oncology lead for the lung cancer disease site group
• From 2016-2021, Dr. Wheatley-Price has served as President of Lung Cancer Canada
• Dr. Wheatley-Price attended medical school in the UK, at the University of St. Andrews (1991-1994) and the University of Manchester (1994 – 1997)
• He received specialist medical oncology training in Wellington, New Zealand, in London at the Royal Free Hospital, Guy’s and St. Thomas’ Hospitals and St. George’s Hospital, and as a Fellow in Lung Cancer Research at Princess Margaret Cancer Centre in Toronto
Stéphanie Michaud, President and CEO at BioCanRx
• Stéphanie is responsible for running all facets of the organization and brings more than 20 years of public, government and private sector experience in research and science & technology innovation policy
• She strives to create partnerships between government, not-for-profits, academia and industry to maximize the impact of research funded by the BioCanRx network on the lives of those affected by cancer
• Prior to joining BioCanRx, Stéphanie was Deputy Director of the flagship Government of Canada Networks Centres of Excellence program
• Dr. Michaud earned a PhD in Organic Chemistry from McGill University. She is involved with a number of not-for-profit organizations and is a member of the Board of Directors of the Stem Cell Network
Kathy Barnard, CEO and Founder, Save Your Skin Foundation
• Kathy founded Save Your Skin Foundation (SYSF), which is a national patient-led not-for-profit group dedicated to the fight against non-melanoma skin cancers, melanoma and ocular melanoma through nationwide education, advocacy, and awareness initiatives
• In 2003, Kathleen was diagnosed with stage IV malignant melanoma, and by the time SYSF was established in 2006, Kathleen’s cancer had spread to her vital organs and her treatment options were limited
• Fortunately, one of her sons discovered a trial treatment taking place in Alberta; this trial would save Kathleen’s life
• SYSF is committed to ensuring equal, timely, affordable, and appropriate access to skin cancer treatment for all Canadians, by engaging in public and private industry, health policy, and systemic treatment access issues with cancer agencies, government, and drug-approval bodies across the country.
